Recurrent Rate in Rectal Cancer Patients with Clinically Suspected Lateral Pelvic Lymph Node Metastasis Following Neoadjuvant Chemoradiotherapy (CRT) and Total Mesorectal Excision (TME)

Thanachai Amornpetsathaporn; Kasidin Vitoopinyoparb; Siripong Sirikurnpiboon; Saraporn Kiattiubolwong; Ponprom Srisakorn

doi:10.64387/tjs.2025.273266

Authors

Thanachai Amornpetsathaporn Division of Colorectal Surgery, Department of Surgery, Rajavithi Hospital
Kasidin Vitoopinyoparb Division of Colorectal Surgery, Department of Surgery, Rajavithi Hospital
Siripong Sirikurnpiboon Division of Colorectal Surgery, Department of Surgery, Rajavithi Hospital
Saraporn Kiattiubolwong Division of Colorectal Surgery, Department of Surgery, Rajavithi Hospital
Ponprom Srisakorn Department of Radiology, Rajavithi Hospital

DOI:

https://doi.org/10.64387/tjs.2025.273266

Keywords:

Lateral pelvic lymph nodes, Rectal cancer, Chemoradiotherapy, Total mesorectal excision

Abstract

Background: The presence of lateral pelvic lymph node (LPLN) metastasis in rectal cancer has been associated with poor prognosis. We aimed to determine the recurrent outcome in patients with clinically suspected LPLN metastasis following neoadjuvant chemoradiotherapy (CRT) and total mesorectal excision (TME)

Materials and Methods: Rectal cancer patients who received neoadjuvant chemoradiotherapy (CRT) and total mesorectal excision (TME) between 2014 and 2023. The Patients’ characteristics, LPLNs status, MRI or CT findings, operative and pathologic findings, recurrent rate, and survival rate were analyzed retrospectively.

Results: Among 131 patients, 88 were in the non-suspected group and 43 in the suspected group before CRT. After CRT, 86 patients in the non-suspected group remained non-suspected, while 2 developed newly suspected LPLN. In the suspected group, 15 patients responded to CRT, whereas 28 remained persistently suspected. The overall recurrence rate was 27.5% (36/131), including 4.6% (6/131) locoregional, 15.3% (20/131) distant, and 7.6% (10/131) both locoregional and distant recurrence.

The newly suspected group had significantly worse recurrence outcomes than the non-suspected group (HR = 8.95, 95% CI: 2.02–39.63; p = 0.004). However, there were no significant differences in recurrence rates for the responded group (HR = 1.11, p = 0.865) and persistently suspected group (HR = 1.23, p = 0.607) compared to the non-suspected group.

Post-treatment analysis revealed that LPLN location in the obturator region and unilateral involvement were significantly associated with increased locoregional recurrence risk. However, only 1 out of 16 patients with local recurrence developed lateral local recurrence.

Conclusion: Neoadjuvant chemoradiotherapy provided comparable local disease control between patients with and without clinically suspected LPLN metastasis in rectal cancer. The progression of LPLNs after CRT was a significant risk factor for recurrence compared to non-progression, highlighting the importance of post-treatment imaging in predicting oncologic outcomes.

References

Sauer R, Liersch T, Merkel S, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012;30(16):1926-33. doi: 10.1200/JCO.2011.40.1836.

van Gijn W, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 2011;12(6):575-82. doi: 10.1016/S1470-2045(11)70097-3.

Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345(9):638-46. doi: 10.1056/NEJMoa010580.

Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355(11):1114-23. doi: 10.1056/NEJMoa060829. Erratum in: N Engl J Med. 2007;357(7):728.

Choi GS, Kim HJ. The role of lateral pelvic lymph node dissection in advanced rectal cancer: a review of current evidence and outcomes. Ann Coloproctol. 2024;40(4):363-74. doi: 10.3393/ac.2024.00521.0074.

Kaur H, Ernst RD, Rauch GM, et al. Nodal drainage pathways in primary rectal cancer: anatomy of regional and distant nodal spread. Abdom Radiol (NY). 2019;44(11):3527-35. doi: 10.1007/s00261-019-02094-0.

Lichliter WE. Techniques in total mesorectal excision surgery. Clin Colon Rectal Surg. 2015;28(1):21-7. doi: 10.1055/s-0035-1545066.

Sugihara K, Kobayashi H, Kato T, et al. Indication and benefit of pelvic sidewall dissection for rectal cancer. Dis Colon Rectum. 2006;49(11):1663-72. doi: 10.1007/s10350-006-0714-z.

Kim TH, Jeong SY, Choi DH, et al. Lateral lymph node metastasis is a major cause of locoregional recurrence in rectal cancer treated with preoperative chemoradiotherapy and curative resection. Ann Surg Oncol. 2008;15(3):729-37. doi: 10.1245/s10434-007-9696-x.

Ogura A, Konishi T, Cunningham C, et al. Neoadjuvant (Chemo) radiotherapy with total mesorectal excision only is not sufficient to prevent lateral local recurrence in enlarged nodes: results of the multicenter lateral node study of patients with low ct3/4 rectal cancer. J Clin Oncol. 2019;37(1):33-43. doi: 10.1200/JCO.18.00032.

Dijkstra EA, Nilsson PJ, Hospers GAP, et al. Locoregional failure during and after short-course radiotherapy followed by chemotherapy and surgery compared with long-course chemoradiotherapy and surgery: a 5-year follow-up of the RAPIDO trial. Ann Surg. 2023;278(4):e766-e772. doi: 10.1097/SLA.0000000000005799.

Hashiguchi Y, Muro K, Saito Y, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. 2020;25(1):1-42. doi: 10.1007/s10147-019-01485-z.

Tsukamoto S, Fujita S, Ota M, et al. Long-term follow-up of the randomized trial of mesorectal excision with or without lateral lymph node dissection in rectal cancer (JCOG0212). Br J Surg. 2020;107(5):586-94. doi: 10.1002/bjs.11513.

Komori K, Fujita S, Mizusawa J, et al. Predictive factors of pathological lateral pelvic lymph node metastasis in patients without clinical lateral pelvic lymph node metastasis (clinical stage II/III): The analysis of data from the clinical trial (JCOG0212). Eur J Surg Oncol 2019;45(3):336-40. doi: 10.1016/j.ejso.2018.11.016.

Glynne-Jones R, Wyrwicz L, Tiret E, et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv22-iv40. doi: 10.1093/annonc/mdx224. Erratum in: Ann Oncol. 2018 Oct 1;29(Suppl 4):iv263. doi: 10.1093/annonc/mdy161.

Fujita S, Mizusawa J, Kanemitsu Y, et al. Mesorectal excision with or without lateral lymph node dissection for clinical stage II/III lower rectal cancer (JCOG0212): A multicenter, randomized controlled, noninferiority trial. Ann Surg. 2017;266(2):201-7. doi: 10.1097/SLA.0000000000002212.

Kanemitsu Y, Komori K, Shida D, et al. Potential impact of lateral lymph node dissection (LLND) for low rectal cancer on prognoses and local control: A comparison of 2 high-volume centers in Japan that employ different policies concerning LLND. Surgery. 2017;162(2):303-14. doi: 10.1016/j.surg.2017.02.005.

Akiyoshi T, Ueno M, Matsueda K, et al. Selective lateral pelvic lymph node dissection in patients with advanced low rectal cancer treated with preoperative chemoradiotherapy based on pretreatment imaging. Ann Surg Oncol. 2014;21(1):189-96. doi: 10.1245/s10434-013-3216-y.

Ishihara S, Kawai K, Tanaka T, et al. Oncological outcomes of lateral pelvic lymph node metastasis in rectal cancer treated with preoperative chemoradiotherapy. Dis Colon Rectum. 2017;60(5):469-76. doi: 10.1097/DCR.0000000000000752.

Law BZY, Yusuf Z, Ng YE, et al. Does adding lateral pelvic lymph node dissection to neoadjuvant chemotherapy improve outcomes in low rectal cancer? Int J Colorectal Dis. 2020;35(8):1387-95. doi: 10.1007/s00384-020-03656-1.

Kim HJ, Choi GS, Park JS, et al. Optimal treatment strategies for clinically suspicious lateral pelvic lymph node metastasis in rectal cancer. Oncotarget. 2017;8(59):100724-33. doi: 10.18632/oncotarget.20121.

Morikawa E, Yasutomi M, Shindou K, et al. Distribution of metastatic lymph nodes in colorectal cancer by the modified clearing method. Dis Colon Rectum. 1994;37(3):219-23. doi: 10.1007/BF02048158.

Bacon HE, Dirbas F, Myers TB, et al. Extensive lymphadenectomy and high ligation of the inferior mesenteric artery for carcinoma of the left colon and rectum. Dis Colon Rectum. 1958;1(6):457-64; discussion 464-5. doi: 10.1007/BF02633415.

Stearns MW Jr, Deddish MR. Five-year results of abdominopelvic lymph node dissection for carcinoma of the rectum. Dis Colon Rectum. 1959;2(2):169-72. doi: 10.1007/BF02616711.

Chang G, Halabi WJ, Ali F. Management of lateral pelvic lymph nodes in rectal cancer. J Surg Oncol. 2023;127(8):1264-10. doi: 10.1002/jso.27317.

Dahmarde H, Parooie F, Salarzaei M. Is 18F-FDG PET/CT an accurate way to detect lymph node metastasis in colorectal cancer: A systematic review and meta-analysis. Contrast Media Mol Imaging. 2020;2020:5439378. doi: 10.1155/2020/5439378.

Beck DE, Reickert CA, Margolin DA, et al. Local recurrence, distant recurrence and survival of rectal cancer. Ochsner J. 2006;6(2):59-63.

Hartvigson PE, Apisarnthanarax S, Schaub S, et al. Radiation therapy dose escalation to clinically involved pelvic sidewall lymph nodes in locally advanced rectal cancer. Adv Radiat Oncol. 2019;4(3):478-86. doi: 10.1016/j.adro.2019.03.007.

Hoshino N, Murakami K, Hida K, et al. Diagnostic accuracy of magnetic resonance imaging and computed tomography for lateral lymph node metastasis in rectal cancer: a systematic review and meta-analysis. Int J Clin Oncol. 2019;24(1):46-52. doi: 10.1007/s10147-018-1349-5.

MERCURY Study Group; Shihab OC, Taylor F, Bees N, et al. Relevance of magnetic resonance imaging-detected pelvic sidewall lymph node involvement in rectal cancer. Br J Surg. 2011;98(12):1798-804. doi: 10.1002/bjs.7662.

Kim HJ, Choi GS, Cho SH, et al. Sequential lateral lymphatic metastasis shows similar oncologic outcomes to upward spread in advanced rectal cancer after preoperative chemoradiotherapy. Dis Colon Rectum. 2024;67(3):359-68. doi: 10.1097/DCR.0000000000002989.